Physician profile
Paul Barnickel
NPI 1669449476
$4,320.40
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,188 · 2020: $809 · 2021: $683 · 2022: $342 · 2023: $180 · 2024: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $618.61 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $541.39 | 2019-2024 | Airsupra |
| Pfizer INC. | $454.82 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $289.74 | 2019-2021 | |
| Glaxosmithkline, LLC. | $284.72 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.30 | 2019-2023 | Jardiance |
| Abbvie INC. | $202.10 | 2021-2023 | Vraylar, Qulipta, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.17 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $163.00 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $157.73 | 2019-2021 | |
| Lilly USA, LLC | $155.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $138.79 | 2019-2021 | |
| Amgen INC. | $136.41 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.23 | 2019-2021 | |
| Amarin Pharma, INC. | $100.60 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $56.68 | 2023-2024 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $56.55 | 2019-2021 | |
| Astellas Pharma US INC | $50.32 | 2019-2021 | |
| Allergan, INC. | $43.25 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.65 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $38.20 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.50 | 2022 | |
| Abbott Laboratories | $28.59 | 2019-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $28.16 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $24.97 | 2019 | |
| Sanofi Pasteur INC. | $24.70 | 2019-2020 | |
| Vivus LLC | $24.45 | 2019 | |
| Lundbeck LLC | $20.03 | 2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $17.16 | 2020 | |
| Dynavax Technologies Corporation | $13.26 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.35 | 2021 | |
| Bausch Health US, LLC | $11.59 | 2019 | |
| Alfasigma USA, INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Barnickel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.